Τίτλος:
An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Allergic rhinoconjunctivitis and chronic urticaria are common histamine-driven diseases, exerting detrimental effects on cognitive functions, sleep, daily activities, and quality of life. Non-sedating second-generation H1-antihistamines are the first-line treatment of choice. Aim of the study was to define the role of bilastine among second-generation H1-antihistamines in the treatment of allergic rhinoconjunctivitis and urticaria in patients of different ages. Methods: An international Delphi study was carried out to assess consensus among experts from 17 European and extra-European countries on three main topics: 1) Burden of disease; 2) Current treatment options; 3) Specific characteristics of bilastine among second-generation antihistamines. Results: Here, we present the results obtained for a selection of 15 out of 27 consensus statements, focused on disease burden, role of second-generation antihistamines and bilastine profile. The rate of concordance was ≥98% for 4 statements, ≥ 96% for 6, ≥ 94% for 3, and ≥90% for 2. Conclusions: The high degree of agreement obtained suggests a wide awareness of the burden of allergic rhinoconjunctivitis and chronic urticaria among experts from all over the world and reflects a broad consensus on the role of second-generation antihistamines in general and of bilastine in particular for their management. © 2023 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Church, M.K.
Canonica, G.W.
Kuna, P.
Maurer, M.
Mösges, R.
Novak, Z.
Papadopoulos, N.G.
Rodriguez del Rio, P.
the Delphi Study Group
Περιοδικό:
Expert Review of Clinical Immunology
Εκδότης:
Taylor and Francis Ltd.
DOI:
10.1080/1744666X.2023.2214729
